晚期胃癌组织切除修复交叉互补基因1表达与奥沙利铂化疗近期疗效的相关性研究

Correlation between expression of ERCC1 and recent curative effect of oxaliplatin chemotherapy in advanced gastric cancer

目的探讨晚期胃癌组织中切除修复交叉互补基因1(excision repair cross-complementing 1,ERCC1)表达与奥沙利铂化疗近期疗效的相关性。方法 56例经病理确诊且具有可评估转移灶的晚期胃癌患者,均接受含奥沙利铂的联合化疗,观察分析化疗近期疗效与ERCC1表达之间的关系。结果 56例患者中进展(PD)26例、稳定(SD)12例,、部分缓解(PR)18例,完全缓解(CR)0例,疾病控制率53.57%,20例患者ERCC1呈阳性表达(35.7%);ERCC1表达与化疗近期疗效具有关联性(χ2=6.95,P=0.009),且关联性较强(r=0.821)。结论晚期胃癌组织中ERCC1基因表达对于接受含奥沙利铂联合化疗疗效预测有指导作用。

Objective To investigate the relationship between expression of excision repair cross-complementation group 1 （ ERCC1 ） and curative effect of oxaliplatin chemotherapy in advanced gastric carcinoma. Methods Fifty-six patients with evaluable metastasis were selected for this study. They were treated with oxaliplatin chemotherapy ,and meanwhile the expression level of ERCC1 was detected. The relationship between ERCC1 expression and disease control response （DCR） were analyzed. Results In 56 pa- tients ,26 were progressive disease （PD）, 12 were stable disease （SD）, and 18 were partial remission （PR）, but nobody was complete remission （CR）. The disease control rate was 53.57%, There were 20 cases having ERCC1 expression （35.7%）. The expression of ERCC1 was associated with the chemotherapy （X2= 6. 95,P = O. 009） , and showed a strong negative correlation （r =-0. 821 ）. Con- clusion ERCC1 gene expression in advanced gastric cancer tissue can be used as a predictive guidance for efficacy of oxaliplatin chemotherapy.